Quick Answer
Traws Pharma, Inc. reported Operating Income Loss of -$142.37 million for the year ending 2024.
- Traws Pharma, Inc. showed a decrease of -601.4% in Operating Income Loss from 2023 to 2024.
- This data is from Traws Pharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2025.
- XBRL data for this metric is available from 2011 to 2024 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2012: -$10.71 million | Q2 2012: -$8.18 million | Q3 2012: $6.92 million | Q4 2012: -$10.31 million | Q1 2013: -$14.99 million | Q2 2013: -$12.57 million | Q3 2013: -$20.10 million | Q4 2013: -$14.56 million | Q1 2014: -$18.73 million | Q2 2014: -$16.76 million | Q3 2014: -$14.89 million | Q4 2014: -$13.36 million | Q1 2015: -$12.35 million | Q2 2015: -$8.96 million | Q3 2015: -$5.88 million | Q1 2016: -$7.52 million | Q2 2016: -$5.40 million | Q3 2016: -$4.32 million | Q1 2017: -$6.79 million | Q2 2017: -$6.07 million | Q3 2017: -$6.76 million | Q1 2018: -$5.90 million | Q2 2018: -$5.64 million | Q3 2018: -$5.59 million | Q1 2019: -$7.24 million | Q2 2019: -$3.63 million | Q3 2019: -$5.10 million | Q1 2020: -$5.13 million | Q2 2020: -$7.34 million | Q3 2020: -$6.27 million | Q1 2021: -$4.10 million | Q2 2021: -$4.65 million | Q3 2021: -$3.99 million | Q1 2022: -$4.13 million | Q2 2022: -$4.12 million | Q3 2022: -$5.64 million | Q1 2023: -$6.14 million | Q2 2023: -$4.61 million | Q3 2023: -$5.09 million | Q1 2024: -$5.21 million | Q2 2024: -$123.35 million | Q3 2024: -$8.54 million | Q1 2025: -$5.20 million | Q2 2025: -$1.25 million | Q3 2025: -$4.06 million.
- Over the full 14 years of available data (2011 to 2024), Traws Pharma, Inc.'s Operating Income Loss has declined by 416.4%.
- Historical annual values: Fiscal year 2024: -$142.37 million | Fiscal year 2023: -$20.30 million | Fiscal year 2022: -$19.63 million | Fiscal year 2021: -$16.50 million | Fiscal year 2020: -$24.99 million | Fiscal year 2019: -$21.70 million | Fiscal year 2018: -$23.28 million | Fiscal year 2017: -$25.74 million | Fiscal year 2016: -$23.70 million | Fiscal year 2015: -$23.97 million | Fiscal year 2014: -$63.74 million | Fiscal year 2013: -$62.22 million | Fiscal year 2012: -$22.28 million | Fiscal year 2011: -$27.57 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: